The Success of Seattle Genetics

Do you know much about cancer research? Have you ever heard of the Biotech Company Seattle Genetics? Success comes in many forms and can be seen as a perspective rather than a physical object. You don’t have to be a millionaire to be successful and it’s rather a state-of-mind. Seattle Genetics is at the apex of the cancer research industry thanks to it’s advanced breakthrough therapies. These therapies have saved many lives and are now setting new industry trends. This Bothell, Washington based company is one of Puget Sound’s largest employers as the company has over 800 employees/staff to date. With the introduction of ADCETRIS (brentuximab vedotin), the company has entered into multiple strategic licensing with prominent organizations such as GlaxoSmithKlein, AbbVie, Genentech, and Pfizer. Now the advanced drug is being used in over 65 countries worldwide.

Seattle Genetics has always stuck to it’s principals. Company CEO and President Clay Siegall implements rigorous research, drug development, and scientific innovation as the backbone for doing business. This well accomplished M.D. has extensive knowledge of the subject, has been around for decades, and has a heart of gold which has given him the title philanthropist. Seattle Genetics doesn’t just depend on it’s flagship drug and many more in the pipeline for future use. As of today the company has about 12 new drugs that are already in the development stages. With such large growth the company is looking to do more hiring to help with it’s high demand as the company is already one of Seattle’s biggest job producers.

The only left to be said is that Seattle Genetics and it’s leadership is setting new trends, changing the status quo, and raising the bar very high for it’s competitors. With profit margins well over $226 Million of last year, Seattle Genetics is looking to rack up well over $250 Million for the year to come.

Leave a Reply

Your email address will not be published. Required fields are marked *